Arecor Therapeutics plc (AIM:AREC)

Market Cap	23.98M
Revenue (ttm)	5.05M
Net Income (ttm)	-10.24M
Shares Out	37.76M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,125
Average Volume	42,847
Open	64.35
Previous Close	63.50
Day's Range	62.38 - 65.00
52-Week Range	35.40 - 95.00
Beta	-0.39
RSI	94.07
Earnings Date	Sep 11, 2025

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 44
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AREC

Financial Performance

In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.